Trial
NCT05785819
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Veralox Therapeutics
Collaborators
—
Condition
Thrombocytopenia, Immune
Intervention
VLX-1005
Why stopped
Veralox Therapeutics Business Decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-25